Table 1 : Six representative platinum-base anticancer drugs in the current clinical trials.

  Cisplatin Carboplatin Oxaliplatin Nedaplatin Lobaplatin Heptaplatin
Year of approval and Market status 1979 Worldwide 1989 Worldwide 2002 Worldwide 1996 Japan 2004 China 2005 Korea
Clinical use Lung, ovarian, testicular, breast and brain cancer, sarcomas, lymphomas Advanced ovarian carcinoma, head and neck, and lung cancer Metastatic colorectal cancer, advanced gastric and ovarian cancer Small and non-small cell lung cancer, head and neck cancer, esophageal, bladder, ovary and cervix cancer Breast, testicular, small cell lung, gastric and ovarian cancer, chronic myeloid leukemia Gastric cancer
Ziora et al.Biochemical Compounds  2016 4:2DOI : 10.7243/2052-9341-4-2